Tasonermin
Tasonermin is a recombinant human tumor necrosis factor alpha (TNF-α) used as an antineoplastic agent via isolated limb perfusion in combination with melphalan for soft tissue sarcoma and unresectable limb melanoma and lymphoma. It exerts direct cytotoxic effects on tumor vasculature and induces apoptosis in tumor cells through TNF receptor activation. Its use is restricted to locoregional administration due to severe systemic toxicity when administered intravenously.
Áreas terapéuticas
Mecanismo de acción
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Tasonermin is a recombinant human tumor necrosis factor alpha (TNF-α) used as an antineoplastic agent via isolated limb perfusion in combination with melphalan for soft tissue sarcoma and unresectable limb melanoma and lymphoma. It exerts direct cytotoxic effects on tumor vasculature and induces apoptosis in tumor cells through TNF receptor activation. Its use is restricted to locoregional administration due to severe systemic toxicity when administered intravenously.
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.
Yes, Tasonermin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107891. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tasonermin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tasonermin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tasonermin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tasonermin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tasonermin"></drugfyi-drug>